Stocks and Investing Stocks and Investing
Tue, April 5, 2022

Mohit Bansal Maintained (VRTX) at Buy with Increased Target to $300 on, Apr 5th, 2022


Published on 2024-10-27 20:18:01 - WOPRAI, Mohit Bansal
  Print publication without navigation


Mohit Bansal of Wells Fargo, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $270 to $300 on, Apr 5th, 2022.

Mohit has made no other calls on VRTX in the last 4 months.



There are 7 other peers that have a rating on VRTX. Out of the 7 peers that are also analyzing VRTX, 2 agree with Mohit's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $269 on, Thursday, March 31st, 2022
  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $222 on, Thursday, January 27th, 2022


These are the ratings of the 5 analyists that currently disagree with Mohit


  • Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $350 on, Monday, April 4th, 2022
  • Liisa Bayko of "Evercore ISI Group" Maintained at Buy with Increased Target to $278 on, Friday, April 1st, 2022
  • Brian Skorney of "Baird" Maintained at Buy and Held Target at $240 on, Wednesday, March 23rd, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Thursday, January 27th, 2022
  • Evan Seigerman of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $274 on, Thursday, January 20th, 2022
Contributing Sources